| Dr Raymond Michael Shaheen I, MD, FACS | |
|
305 South Dr, Suite 7, Mountain View, CA 94040-4200 | |
| (650) 965-1909 | |
| (650) 965-1944 |
| Full Name | Dr Raymond Michael Shaheen I |
|---|---|
| Gender | Male |
| Speciality | Vascular Surgery |
| Experience | 28 Years |
| Location | 305 South Dr, Mountain View, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114997434 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0129X | Surgery - Vascular Surgery | A63071 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| El Camino Hospital | Mountain view, CA | Hospital |
| Entity Name | Raymond M Shaheen Md Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992982144 PECOS PAC ID: 2567531361 Enrollment ID: O20080520000442 |
News Archive
Vitalitec International, Plymouth, Massachusetts, is pleased to announce the acquisition of the ENCLOSE II Anastomosis Assist Device from Novare Surgical Systems. The ENCLOSE II Anastomosis Assist Device was developed by Thomas Fogarty, MD, and is designed to assist surgeons in performing "off pump" Coronary Artery Bypass Procedures.
Wolbachia bacteria are widely studied for possible properties to block transmission of viruses like chikungunya, dengue and zika.
A widely-used arthritis drug reduces the incidence of non-melanoma skin cancers - the most common cancers in humans - according to a study published this week in the Journal of the National Cancer Institute. The COX-2 inhibitor celecoxib (brand name Celebrex), which is currently approved for the treatment of osteoarthritis, rheumatoid arthritis and acute pain in adults led to a 62 percent reduction in non-melanoma skin cancers, which includes basal cell carcinomas and squamous cell carcinomas.
The final results of a six-month, multi-center, open-label Phase 3 study of VIAject® (more-rapid-acting injectable human insulin) versus regular human insulin (RHI) in 471 patients with type 2 diabetes were presented today by Helena Rodbard, M.D., at the 70th Scientific Sessions of the American Diabetes Association. Dr. Rodbard was a principal investigator of this study, which was designed to evaluate the safety and efficacy of VIAject® versus regular human insulin when used in combination with insulin glargine.
Database enhancements developed at The Cancer Institute of New Jersey (CINJ) are helping physicians use technology to further ensure safety in the delivery of chemotherapy.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Raymond Michael Shaheen I, MD, FACS 305 South Dr, Suite 7, Mountain View, CA 94040-4200 Ph: (650) 965-1909 | Dr Raymond Michael Shaheen I, MD, FACS 305 South Dr, Suite 7, Mountain View, CA 94040-4200 Ph: (650) 965-1909 |
News Archive
Vitalitec International, Plymouth, Massachusetts, is pleased to announce the acquisition of the ENCLOSE II Anastomosis Assist Device from Novare Surgical Systems. The ENCLOSE II Anastomosis Assist Device was developed by Thomas Fogarty, MD, and is designed to assist surgeons in performing "off pump" Coronary Artery Bypass Procedures.
Wolbachia bacteria are widely studied for possible properties to block transmission of viruses like chikungunya, dengue and zika.
A widely-used arthritis drug reduces the incidence of non-melanoma skin cancers - the most common cancers in humans - according to a study published this week in the Journal of the National Cancer Institute. The COX-2 inhibitor celecoxib (brand name Celebrex), which is currently approved for the treatment of osteoarthritis, rheumatoid arthritis and acute pain in adults led to a 62 percent reduction in non-melanoma skin cancers, which includes basal cell carcinomas and squamous cell carcinomas.
The final results of a six-month, multi-center, open-label Phase 3 study of VIAject® (more-rapid-acting injectable human insulin) versus regular human insulin (RHI) in 471 patients with type 2 diabetes were presented today by Helena Rodbard, M.D., at the 70th Scientific Sessions of the American Diabetes Association. Dr. Rodbard was a principal investigator of this study, which was designed to evaluate the safety and efficacy of VIAject® versus regular human insulin when used in combination with insulin glargine.
Database enhancements developed at The Cancer Institute of New Jersey (CINJ) are helping physicians use technology to further ensure safety in the delivery of chemotherapy.
› Verified 2 days ago
Arhana Chattopadhyay, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2350 Toledo Ter, Mountain View, CA 94043 Phone: 508-431-7943 | |
Dr. Maciej J Kieturakis, Surgery Medicare: Accepting Medicare Assignments Practice Location: 305 South Dr, #7, Mountain View, CA 94040 Phone: 650-938-6600 Fax: 650-938-6601 | |
Dr. Alexander Quidayan Ereso, MD Surgery Medicare: Medicare Enrolled Practice Location: 525 South Dr, Suite 203, Mountain View, CA 94040 Phone: 650-964-6600 Fax: 650-964-7639 | |
Dr. Rosa Lisa Dell'oca, M.D. Surgery Medicare: May Accept Medicare Assignments Practice Location: 525 South Drive, Suite 215, Mountain View, CA 94040 Phone: 650-468-0840 | |
Dr. Danagra Georgia Ikossi, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 701 E El Camino Real, Mountain View, CA 94040 Phone: 650-934-7000 | |
Richard Slavin, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2350 W El Camino Real, 6th Floor, Mountain View, CA 94040 Phone: 650-934-7221 |